At a median follow-up of 60.9 months, median EFS was 74.1 months in the pembrolizumab arm and not reached in the placebo arm.
|Videos|January 6, 2023
Dr. Kelly Stratton discusses 2022 SUO Kidney Cancer Course
Author(s)Urology Times staff
“It's very interesting to see how this continues to progress as a field,” says Kelly L. Stratton, MD FACS.
Advertisement
In this video, Kelly L. Stratton, MD, FACS, discusses the Kidney Cancer Course held during the 2022 Society of Urologic Oncology Annual Meeting. Stratton is an assistant professor of urologic oncology at the University of Oklahoma, Oklahoma City.
Advertisement
Related to this article
Take a look through some of the notable data presentations at this year's ESMO Congress.
Advertisement
Advertisement
Trending on Urology Times
1
ESMO 2026: Key presentations across genitourinary oncology
2
Darolutamide associated with less cognitive change than enzalutamide in prostate cancer
3
How PSMA-PET shapes staging and recurrence workup in prostate cancer
4
KLK2-comPAS trial explores dual T-cell engagement in mCRPC
5